← ANALYST RATINGS · TIPRANKS
Alumis Inc. (ALMS): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy1 Hold0 Sell
Ratings of 8 analysts in the last 3 months12-month forecast
Based on 8 price targets given in the last 3 months, the average target is $29.50, the highest $44.00, the lowest $15.00. The average is +382.0% from the last price of $6.12.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $6.50 → $6.00−7.7% | Hold | −2.0% | Reiterated | 15.10.26on TipRanks 08:07 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $6.50 → $6.00−7.7% | Sell | −2.0% | Downgrade | 15.10.26on TipRanks 08:07 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $6.50 → $6.00−7.7% | Hold | −2.0% | Reiterated | 15.10.26on TipRanks 08:07 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $6.00 → $5.50−8.3% | Sell | −10.1% | Reiterated | 15.10.26on TipRanks 08:07 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $6.00 | Hold | −2.0% | Upgrade | 15.10.26on TipRanks 08:07 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $6.50 → $6.00−7.7% | Hold | −2.0% | Reiterated | 15.10.26on TipRanks 08:07 | — | |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $15.00 | Buy | +145.1% | Reiterated | 05.10.26on TipRanks 06:55 | −0.8%next day +0.8% · 5 days +2.8% | ↗ |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $25.00 | Buy | +308.5% | Reiterated | 09.09.26on TipRanks 13:15 | −6.9%next day +1.6% · 5 days −17.9% | ↗ |
| Christopher Raymond★★★★★★★★★★#4074 · hits 45% · avg +2.6% | Raymond James | — | Buy | — | Reiterated | 02.09.26on TipRanks Sep 3 10:30 | +8.8%next day +8.7% · 5 days −3.4% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | — | Hold | — | Downgrade | 02.09.26on TipRanks Sep 3 05:35 | +8.8%next day +8.7% · 5 days −3.4% | ↗ |
| Jeff Jones★★★★★★★★★★#749 · hits 46% · avg +20.3% | Oppenheimer | $55.00 → $37.00−32.7% | Buy | +504.6% | Reiterated | 02.09.26on TipRanks 07:45 | +8.8%next day +8.7% · 5 days −3.4% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $39.00 → $29.00−25.6% | Buy | +373.9% | Reiterated | 02.09.26on TipRanks 06:50 | +8.8%next day +8.7% · 5 days −3.4% | ↗ |
| Brian Skorney★★★★★★★★★★#12116 · hits 37% · avg −5.6% | Robert W. Baird | $35.00 → $27.00−22.9% | Buy | +341.2% | Reiterated | 01.09.26on TipRanks 15:30 | −55.9%next day +8.8% · 5 days +3.4% | ↗ |
| Alex Thompson CFA★★★★★★★★★★#60 · hits 73% · avg +50.6% | Stifel Nicolaus | $44.00 | Buy | +619.0% | Reiterated | 13.08.26on TipRanks 11:35 | −5.2%next day +3.9% · 5 days −4.4% | ↗ |
| Janani Sundararajan★★★★★★★★★★#11009 · hits 38% · avg −15.9% | Chardan Capital | $40.00 | Buy | +553.6% | Reiterated | 19.05.26on TipRanks 08:10 | +2.4%next day +1.4% · 5 days −3.2% | ↗ |
| Thomas Smith★★★★★★★★★★#45 · hits 57% · avg +51.1% | Leerink Partners | $32.00 | Buy | +422.9% | Reiterated | 15.05.26on TipRanks 11:20 | −5.9%next day −7.5% · 5 days −4.6% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Alumis Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $29.50 at a price of $7.39 (+299.2%); now: $29.50 at $6.12 (+382.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 16 | 7 | 8 | 7 | 11 | 10 |
| Buy | 6 | 3 | 3 | 2 | 4 | 3 |
| Hold | 1 | 1 | 1 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 12.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.75 (from $-0.83 to $-0.61). Last quarter: $-1.11.
Sales
Next quarter’s sales estimate — $2M (from $0M to $5M). Last quarter: $2M.
Best top-analyst consensus in the sector · Healthcare
About Alumis Inc.
- CEO: Martin Babler
- Employees: 237
- 280 East Grand Avenue, South San Francisco, CA, 94080, US
- www.alumis.com
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Data from the stock’s TipRanks forecast page, read 82 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗